PACE Launches £6M Funding Round to Fight Global AMR Crisis
PACE, a significant UK public-private collaboration, has launched its third £6 million funding round to combat resistant bacterial infections and the escalating global AMR crisis. The initiative, backed by a wider £30m investment, aims to foster bold innovation in antimicrobial research.
PACE, supported by partners like Innovate UK, LifeArc, and Medicines Discovery Catapult, seeks novel therapies targeting fresh mechanisms of action. The funding programme, initiated by BARDA and Venatorx Pharmaceuticals, now involving Basilea Pharmaceutica AG, focuses on life-threatening infections such as lower respiratory tract, urinary tract, and bloodstream infections.
Successful applicants will receive up to £1m over two years, along with expert guidance, strategic planning, and network access. The call for projects emphasises the urgent need for innovative solutions, as over 80% of recent antibacterial drugs are based on existing classes, limiting their effectiveness against resistant strains.
With resistant bacterial infections projected to cause more than eight million deaths annually by 2050 and cost the global economy an estimated $100 trillion, PACE's funding round encourages AMR innovators worldwide to apply. The programme aims to accelerate the development of novel antibiotics, addressing the growing threat of antimicrobial resistance.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
